AZD3366

AZD3366 (also known as APT102) is a long-acting, engineered recombinant protein based on an optimized CD39L3 human apyrase. Developed using recombinant DNA technology in Chinese hamster ovary cells, it acts by hydrolyzing extracellular ATP and ADP to AMP, which is then converted to adenosine by endogenous CD73. This mechanism leads to inhibition of inflammation and thrombosis through broad attenuation of platelet activation at multiple P2 receptors (P2X1, P2Y1, P2Y12), providing more complete inhibition than current P2Y12 inhibitors like ticagrelor or clopidogrel. Preclinical studies have shown that AZD3366 reduces platelet aggregation and provides tissue protection in models of cardiovascular disease by limiting myocardial injury and reducing infarct size. It also demonstrates anti-inflammatory effects and may preserve vascular integrity with a lower risk of bleeding compared to standard antiplatelet therapies. The drug is being developed primarily for cardiovascular indications such as prevention of thrombosis and reduction of myocardial infarct size[1][3][5][7].

Brand names

Luminase

Other names

CD39L3 human apyrase (optimized recombinant form)